CLINICAL DIAGNOSIS AND SAFETY OF VILDAGLIPTIN VERSUS GLIMEPIRIDE WITH METFORMIN OVER PATIENTS OF TYPE-2 DIABETES MELLITUS

The aim of the study to compare the efficacy of vildagliptin (50 mg) and glimepiride (2 mg) metformin (500 mg) for type-2 diabetes mellitus. Vildagliptin and glimepiride are found to be regulated the blood plasma glucose by stimulating beta cell in the pancreas. The treatment course duration of 34 weeks comparative observational study was conducted over 160 patients with type-2 diabetes mellitus was recognized. Group A (n=80) was treated with vildagliptin (50 mg) with a combination of metformin (500 mg). Group B (n = 80) was treated with glimepiride (2 mg) with a combination of metformin (500 mg) with fixed dosage was given daily twice. The baseline of HbA1c from > 7.0% to <10.5%. The tests were performed by the help of vitros 250 and sysmex XN 1000 and 350. Thus, the performance of the t-test was found to play a significant role. Group A and group B have shown a greater reduction in plasma glucose fasting plasma glucose reduced up to 47.9mg/dl (p<0.000) in vildagliptin group versus glimepiride group 36.84 mg/dl (p<0.000), postprandial glucose reduced up to 54.67 mg/dl (p<0.000) in vildagliptin group and glimepiride group reduced up to 42.94 mg/dl (p<0.000) and HbA1c reduced up to 1.21%(p<1.0) in vildagliptin group versus glimepiride group reduced up to 0.90%(p<1.0). The body weight was increased by 0.93 kg with glimepiride (Group B) and reduced by 0.74 kg with vildagliptin (Group A). In this observation vildagliptin group results were found to be potential treatment with more benefits with comparison to glimepiride. vildagliptinwas good for pancreatic beta cell, with lower risk of hypoglycemia comparison to glimepiride